These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 7974335

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level.
    Lechner K, Nowotny C, Krinninger B, Zegner M, Deutsch E.
    Thromb Haemost; 1979 Feb 15; 40(3):478-85. PubMed ID: 425062
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Development of factor VIII antibody in haemophilic monozygotic twins. European Study Group of Factor VIII Antibody.
    Scand J Haematol; 1979 Jul 15; 23(1):64-8. PubMed ID: 573920
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D, Reyes H, Felch M, Sakurai Y.
    Haematologica; 2000 Oct 15; 85(10 Suppl):86-8. PubMed ID: 11187882
    [Abstract] [Full Text] [Related]

  • 50. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
    Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ.
    Thromb Haemost; 1997 Sep 15; 78(3):1027-9. PubMed ID: 9308748
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors.
    Ewing NP, Sanders NL, Dietrich SL, Kasper CK.
    JAMA; 1988 Jan 01; 259(1):65-8. PubMed ID: 3119878
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. [Cellular immunology status in 5 hemophilic patients with inhibitors subjected to massive therapy with factor VIII concentrate].
    Aznar JA, Jorquera JI, González Molina A, Carbonell F, Trenor A, Sánchez Cuenca JM, de Andrés R.
    Sangre (Barc); 1983 Jan 01; 28(5):663-4. PubMed ID: 6420915
    [No Abstract] [Full Text] [Related]

  • 60. Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Abildgaard CF.
    Semin Hematol; 1991 Apr 01; 28(2 Suppl 1):44. PubMed ID: 1908127
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.